Paper Details

  1. Home
  2. Paper Details

Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis.

Author: JinXianhui, WuJiaqi, YanGuanghui, ZhangQingsheng

Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.

Overview

Denosumab is effective in increasing bone mineral density in postmenopausal osteoporosis patients but has not been shown to have a benefit over bisphosphonates in reducing the risk of fracture. More long-term follow-up studies are needed to identify potential complications of denosumab.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The standard treatment for osteoporosis was controversial. Denosumab and bisphosphonates were two most common drugs. The purpose of this study was to compare the efficacy and safety of denosumab with bisphosphonates to treat osteoporosis. METHODS: Published literatures, only including r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6090940/

データ提供：米国国立医学図書館（NLM）

Navigating the Desert of Osteoporosis: Denosumab vs. Bisphosphonates

[Postmenopausal osteoporosis] is a [common condition] that can lead to [bone fractures]. This [meta-analysis] compares the [efficacy] and [safety] of two commonly used [osteoporosis treatments], [denosumab] and [bisphosphonates]. The authors reviewed [11 studies] involving [5446 patients] to assess the [effectiveness] of these drugs in [reducing fracture risk].

A Comparative Look at Osteoporosis Treatments

The meta-analysis found no [significant difference] between [denosumab] and [bisphosphonates] in terms of [reducing fracture risk]. However, [denosumab] was associated with a [significant increase] in [bone mineral density (BMD)] compared to [bisphosphonates].

Choosing the Right Path for Bone Health

Imagine a [camel] crossing a [desert] – the [path] can be [difficult] and [unpredictable]. This study offers a [comparative analysis] of two [potential paths] for [managing osteoporosis]. While [denosumab] and [bisphosphonates] may offer [similar benefits] in [reducing fracture risk], the study suggests that [denosumab] may be [more effective] at [improving BMD].

Dr. Camel's Conclusion

This meta-analysis provides valuable insights into the [effectiveness] of [denosumab] and [bisphosphonates] in [treating postmenopausal osteoporosis]. While both drugs appear to be [equally effective] in [reducing fracture risk], [denosumab] may offer a [potential advantage] in terms of [improving BMD]. It's like choosing the [right path] in the [desert] – a [careful assessment] of the [benefits] and [risks] is essential to [ensure optimal bone health].

Date :
  1. Date Completed 2019-01-07
  2. Date Revised 2019-01-07
Further Info :

Pubmed ID

30071889

DOI: Digital Object Identifier

PMC6090940

Related Literature

Article Analysis
・Effective treatment of osteoporosis
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.